The Aptima Virology portfolio delivers on the Hologic promise of innovation through life-changing viral testing for viruses that impact patients across the globe.

Deliver Precise Results

The industry-leading accuracy of Aptima assays for HIV-1, HCV and HBV give you the confidence to deliver reliable, repeatable results that you and your patients can count on.

Experience Optimal Performance

Aptima Virology assays operate on the Panther® system, which means ultra-fast, true sample-to-result automation—everything your lab needs to meet today’s molecular testing demands.

Applied Innovation in Virology Testing

Hologic and the Aptima Virology portfolio have a legacy of innovation and leadership, driving critical advances in the diagnosis and monitoring of Human Immunodeficiency Virus (HIV) and Hepatitis B and C viruses (HBV and HCV). This legacy began with the FDA approval of qualitative nucleic acid amplification tests (NAATs) for HIV-1 and HCV in the early 2000s. It continues with viral load testing for HIV-1, HCV, and HBV.

Today, the Aptima Virology portfolio is a critical aid in the clinical management of HIV-1, HCV, and HBV. Run on the fully automated Panther system, these assays use proprietary real-time transcription mediated amplification (TMA) technology from Hologic.